MX2010013019A - Sales antivirales. - Google Patents

Sales antivirales.

Info

Publication number
MX2010013019A
MX2010013019A MX2010013019A MX2010013019A MX2010013019A MX 2010013019 A MX2010013019 A MX 2010013019A MX 2010013019 A MX2010013019 A MX 2010013019A MX 2010013019 A MX2010013019 A MX 2010013019A MX 2010013019 A MX2010013019 A MX 2010013019A
Authority
MX
Mexico
Prior art keywords
salts
treatment
antiviral
hrv
relates
Prior art date
Application number
MX2010013019A
Other languages
English (en)
Spanish (es)
Inventor
Ryan Jane
Anne Butt Margaret
Original Assignee
Biota Scient Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management Pty Ltd filed Critical Biota Scient Management Pty Ltd
Publication of MX2010013019A publication Critical patent/MX2010013019A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2010013019A 2008-05-27 2009-05-27 Sales antivirales. MX2010013019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5634108P 2008-05-27 2008-05-27
PCT/AU2009/000663 WO2009143571A1 (en) 2008-05-27 2009-05-27 Antiviral salts

Publications (1)

Publication Number Publication Date
MX2010013019A true MX2010013019A (es) 2011-03-21

Family

ID=41376478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013019A MX2010013019A (es) 2008-05-27 2009-05-27 Sales antivirales.

Country Status (14)

Country Link
US (2) US8580791B2 (enExample)
EP (1) EP2297141B1 (enExample)
JP (1) JP5469662B2 (enExample)
KR (1) KR20110019759A (enExample)
CN (1) CN102046621B (enExample)
AU (1) AU2009253738B2 (enExample)
BR (1) BRPI0912038A2 (enExample)
CA (1) CA2725618C (enExample)
CO (1) CO6280534A2 (enExample)
EA (1) EA020455B1 (enExample)
MX (1) MX2010013019A (enExample)
NZ (1) NZ590286A (enExample)
WO (1) WO2009143571A1 (enExample)
ZA (1) ZA201009284B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603040A (en) * 2010-04-15 2015-03-27 Biota Scient Management Compound for treatment of respiratory condition or disease
US8796273B2 (en) * 2010-06-25 2014-08-05 Biota Scientific Management Pty Ltd Compound for the treatment of enteroviruses
CN102617462B (zh) * 2012-02-28 2014-02-12 南京大学 特异性抑制肌肉微小核糖核酸的化合物及其合成方法和应用
US9802926B2 (en) * 2014-06-20 2017-10-31 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
WO2022235874A1 (en) * 2021-05-05 2022-11-10 Emory University Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto
WO2024192149A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of treating enterovirus in chronic obstructive pulmonary disease patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79215B (enExample) 1982-06-07 1984-10-22 Glaxo Group Ltd
GB2162522B (en) 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5545653A (en) * 1995-06-07 1996-08-13 Eli Lilly And Company Anti-viral compounds
US5693661A (en) * 1995-06-07 1997-12-02 Eli Lilly And Company Anti-viral compounds
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
WO1998031363A1 (en) * 1997-01-22 1998-07-23 Eli Lilly And Company Anti-viral compounds
AU7715198A (en) * 1997-06-04 1998-12-21 Eli Lilly And Company Anti-viral compounds
US6358971B1 (en) * 1998-05-20 2002-03-19 Eli Lilly And Company Anti-viral compounds
JP2002515433A (ja) * 1998-05-20 2002-05-28 イーライ・リリー・アンド・カンパニー 抗ウイルス化合物
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents

Also Published As

Publication number Publication date
BRPI0912038A2 (pt) 2017-06-20
WO2009143571A1 (en) 2009-12-03
CA2725618C (en) 2016-04-12
NZ590286A (en) 2011-08-26
AU2009253738B2 (en) 2012-12-13
CN102046621B (zh) 2014-11-12
KR20110019759A (ko) 2011-02-28
US8580791B2 (en) 2013-11-12
EP2297141B1 (en) 2015-10-21
CA2725618A1 (en) 2009-12-03
ZA201009284B (en) 2012-06-27
CN102046621A (zh) 2011-05-04
US20140179710A1 (en) 2014-06-26
JP5469662B2 (ja) 2014-04-16
AU2009253738A1 (en) 2009-12-03
EA201001835A1 (ru) 2011-06-30
US20110144118A1 (en) 2011-06-16
CO6280534A2 (es) 2011-05-20
US9206171B2 (en) 2015-12-08
JP2011520991A (ja) 2011-07-21
EA020455B1 (ru) 2014-11-28
EP2297141A4 (en) 2012-04-25
EP2297141A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EA201100390A1 (ru) Соединения для лечения гепатита с
PH12013502033A1 (en) Pyrimidine derivatives for the treatment of viral infections
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
ES2572329A2 (es) Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc
EA201270616A1 (ru) Ингибиторы вируса гепатита с
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MY173422A (en) Purine derivatives for the treatment of viral infections
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MY202109A (en) Viral replication inhibitors
TN2011000482A1 (en) Organic compounds and their uses
PH12015502230A1 (en) Novel viral replication inhibitors
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
WO2013106689A8 (en) Hcv ns3 protease inhibitors
MX343505B (es) Metodos y composiciones para inhibir la transmision del vih.
MX2010013019A (es) Sales antivirales.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
TN2011000089A1 (en) Compounds for the treatment of hepatitis c
TH149188A (th) สารยับยั้งไวรัสตับอักเสบ c

Legal Events

Date Code Title Description
FG Grant or registration